24. Conklin KA (2004) Cancer chemotherapy and antioxidants. J Nutr 134: 3201S–3204S. 25. Fonseca-Silva F, Inacio JD, Canto-Cavalheiro MM, meida-Amaral EE (2011) Reactive oxygen species production and mitochondrial dysfunction contribute to quercetin induced death in Leishmania amazonensis. PLoS One 6: e14666. 26. Venkateswarlu K, Denning DW, Kelly SL (1997) Inhibition and interaction of cytochrome P450 of Candida krusei with azole antifungal drugs. J Med Vet Mycol 35: 19–25. 27. Van Hellemond JJ, Tielens AG (2006) Adaptations in the lipid metabolism of the protozoan parasite Trypanosoma brucei. FEBS Lett 580: 5552–5558. 28. Cohen BE (1998) Amphotericin B toxicity and lethality: a tale of two channels. International Journal of Pharmaceutics 162: 95–106. 29. Chen CK, Doyle PS, Yermalitskaya LV, Mackey ZB, Ang KK, et al. (2009) Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit. PLoS Negl Trop Dis 3: e372. 30. Lepesheva GI, Ott RD, Hargrove TY, Kleshchenko YY, Schuster I, et al. (2007) Sterol 14alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth. Chem Biol 14: 1283–1293. 31. Lepesheva GI, Hargrove TY, Kleshchenko Y, Nes WD, Villalta F, et al. (2008) CYP51: A major drug target in the cytochrome P450 superfamily. Lipids 43: 1117–1125. 32. Maxfield FR, Tabas I (2005) Role of cholesterol and lipid organization in disease. Nature 438: 612–621. 33. Heese-Peck A, Pichler H, Zanolari B, Watanabe R, Daum G, et al. (2002) Multiple functions of sterols in yeast endocytosis. Mol Biol Cell 13: 2664–2680. 34. Olsher M, Yoon SI, Chong PL (2005) Role of sterol superlattice in free radical- induced sterol oxidation in lipid membranes. Biochemistry 44: 2080–2087. 35. Rakotomanga M, Blanc S, Gaudin K, Chaminade P, Loiseau PM (2007) Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob Agents Chemother 51: 1425–1430. CYP5122A1, a Novel Cytochrome P450 of Leishmania 36. Croft SL, Engel J (2006) Miltefosine–discovery of the antileishmanial activity of phospholipid derivatives. Trans R Soc Trop Med Hyg 100 Suppl 1: S4–S8. 37. Arora A, Raghuraman H, Chattopadhyay A (2004) Influence of cholesterol and ergosterol on membrane dynamics: a fluorescence approach. Biochem Biophys Res Commun 318: 920–926. 38. Iyer JP, Kaprakkaden A, Choudhary ML, Shaha C (2008) Crucial role of cytosolic tryparedoxin peroxidase in Leishmania donovani survival, drug response and virulence. Mol Microbiol 68: 372–391. 39. Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain- terminating inhibitors. Proc Natl Acad Sci USA 74: 5463–5467. 40. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, et al. (2003) Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 31: 3497–3500. 41. Jones DT (1999) Protein secondary structure prediction based on position- specific scoring matrices. J Mol Biol 292: 195–202. 42. Schwede T, Kopp J, Guex N, Peitsch MC (2003) SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res 31: 3381–3385. 43. Morris AL, MacArthur MW, Hutchinson EG, Thornton JM (1992) Stereo- chemical quality of protein structure coordinates. Proteins 12: 345–364. 44. Hooft RW, Vriend G, Sander C, Abola EE (1996) Errors in protein structures. Nature 381: 272. 45. Jain R, Ghoshal A, Mandal C, Shaha C (2010) Leishmania cell surface prohibitin: role in host-parasite interaction. Cell Microbiol 12: 432–452. 46. Arthington-Skaggs BA, Jradi H, Desai T, Morrison CJ (1999) Quantitation of ergosterol content: novel method for determination of fluconazole susceptibility of Candida albicans. J Clin Microbiol 37: 3332–3337. PLoS ONE | www.plosone.org 16 September 2011 | Volume 6 | Issue 9 | e25273